CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于癌症免疫治疗的基于纳米颗粒的嵌合抗原受体疗法
英文原题：Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.
查看英文原题
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
采用嵌合抗原受体（CAR）工程化T细胞（CAR-T）的过继细胞疗法已成为治疗血液系统恶性肿瘤的一种创新免疫疗法。然而，CAR-T 治疗实体瘤的疗效有限、制备流程复杂且制造成本过高，仍是其局限。纳米技术为传统CAR-T 疗法提供了一种替代选择。凭借独特的理化性质，纳米颗粒既可作为药物递送平台，也可靶向特定细胞。基于纳米颗粒的CAR疗法不仅可用于T细胞，也可用于CARNK 细胞和CAR巨噬细胞，有助于弥补这些细胞疗法的部分局限。本综述重点介绍基于纳米颗粒的先进CAR免疫细胞疗法及免疫细胞重编程的未来展望。
展开英文摘要原文
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment.
However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells.
Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.
论文信息
- 作者
- Shin S、Lee P、Han J、Kim SN、Lim J、Park DH、Paik T、Min J
- 第一作者单位
- Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.South Korea
- 通讯作者单位
- Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. parkwr@skku.edu.South Korea
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Tissue engineering and regenerative medicine2023 Jun
- 原文标识
- PubMed 36867402 · DOI 10.1007/s13770-022-00515-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →